Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 4
1999 3
2000 4
2001 10
2002 5
2003 6
2004 5
2005 10
2006 9
2007 5
2008 5
2009 4
2010 11
2011 6
2012 12
2013 14
2014 22
2015 32
2016 23
2017 34
2018 20
2019 24
2020 19
2021 22
2022 26
2023 8
2024 21
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R. Ueda R. Oncology. 2015;89 Suppl 1:16-21. doi: 10.1159/000431059. Epub 2015 Nov 10. Oncology. 2015. PMID: 26550987 Review.
Mogamulizumab (KW-0761) is a humanized anti-CCR4 monoclonal antibody with a defucosylated Fc region (Potelligent Technology), which markedly enhances antibody-dependent cellular cytotoxicity by increasing its binding affinity to the Fcx03B3; receptor e …
Mogamulizumab (KW-0761) is a humanized anti-CCR4 monoclonal antibody with a defucosylated Fc region (Potelligent Techno …
Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
Tawa M, Kopp E, McCann S, Cantrell W. Tawa M, et al. Clin J Oncol Nurs. 2019 Aug 1;23(4):E73-E80. doi: 10.1188/19.CJON.E73-E80. Clin J Oncol Nurs. 2019. PMID: 31322628 Review.
BACKGROUND: Cutaneous T-cell lymphoma (CTCL), including subtypes mycosis fungoides (MF) and Sezary syndrome (SS), represents a rare group of non-Hodgkin lymphomas. Mogamulizumab is a first-in-class monoclonal antibody that selectively binds to C-C chemokine receptor …
BACKGROUND: Cutaneous T-cell lymphoma (CTCL), including subtypes mycosis fungoides (MF) and Sezary syndrome (SS), represents a rare group of …
Regulatory T cells in cancer immunotherapy.
Tanaka A, Sakaguchi S. Tanaka A, et al. Cell Res. 2017 Jan;27(1):109-118. doi: 10.1038/cr.2016.151. Epub 2016 Dec 20. Cell Res. 2017. PMID: 27995907 Free PMC article. Review.
Various cell surface molecules, including chemokine receptors such as CCR4, that are specifically expressed by effector Treg cells can be the candidates for depleting effector Treg cells by specific cell-depleting monoclonal antibodies. In addition, other imm …
Various cell surface molecules, including chemokine receptors such as CCR4, that are specifically expressed by effector Treg cells ca …
Identification of the Binding Epitope of an Anti-mouse CCR4 Monoclonal Antibody, C(4)Mab-1.
Asano T, Suzuki H, Tanaka T, Kaneko MK, Kato Y. Asano T, et al. Monoclon Antib Immunodiagn Immunother. 2022 Aug;41(4):214-220. doi: 10.1089/mab.2022.0015. Epub 2022 Aug 2. Monoclon Antib Immunodiagn Immunother. 2022. PMID: 35917564
C-C chemokine receptor 4 (CCR4) is one of G protein-coupled receptors, and interacts with chemokines, CCL17 and CCL22. ...Therefore, CCR4 may be a potential therapeutic option for T cell malignancies. C(4)Mab-1 is a novel anti-mouse CCR4 (mCCR4) monoclonal …
C-C chemokine receptor 4 (CCR4) is one of G protein-coupled receptors, and interacts with chemokines, CCL17 and CCL22. ...Therefore, …
Development of a Novel Anti-Mouse CCR4 Monoclonal Antibody (C(4)Mab-1) by N-Terminal Peptide Immunization.
Takei J, Suzuki H, Asano T, Tanaka T, Kaneko MK, Kato Y. Takei J, et al. Monoclon Antib Immunodiagn Immunother. 2022 Apr;41(2):87-93. doi: 10.1089/mab.2021.0064. Monoclon Antib Immunodiagn Immunother. 2022. PMID: 35471046
Two CCR4 ligands (CCL17 and CCL22) bind to CCR4 that mediate physiological and pathological functions of T cell immune responses. Anti-CCR4 monoclonal antibody (mAb) mogamulizumab is approved for adult T cell leukemia/lymphoma and cutaneous T ce …
Two CCR4 ligands (CCL17 and CCL22) bind to CCR4 that mediate physiological and pathological functions of T cell immune respons …
Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
Kanazawa T, Hiramatsu Y, Iwata S, Siddiquey M, Sato Y, Suzuki M, Ito Y, Goshima F, Murata T, Kimura H. Kanazawa T, et al. Clin Cancer Res. 2014 Oct 1;20(19):5075-84. doi: 10.1158/1078-0432.CCR-14-0580. Epub 2014 Aug 12. Clin Cancer Res. 2014. PMID: 25117294
To identify a molecular-targeted therapy for EBV-associated T/NK-LPDs, we investigated whether CC chemokine receptor 4 (CCR4) was expressed on EBV-infected T and/or NK cells and whether a humanized anti-CCR4 monoclonal antibody, mogamulizumab, was effe …
To identify a molecular-targeted therapy for EBV-associated T/NK-LPDs, we investigated whether CC chemokine receptor 4 (CCR4) was exp …
Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment.
Cerroni L. Cerroni L. Semin Cutan Med Surg. 2018 Mar;37(1):2-10. doi: 10.12788/j.sder.2018.002. Semin Cutan Med Surg. 2018. PMID: 29719014 Review.
Conventional systemic chemotherapy and single-agent chemotherapy (eg, gemcitabine) give usually good results in advanced MF, but recurrences are the rule. Monoclonal antibodies directed against cluster of differentiation (CD)52 (alemtuzumab), CD30 (brentuximab vedot …
Conventional systemic chemotherapy and single-agent chemotherapy (eg, gemcitabine) give usually good results in advanced MF, but recurrences …
[Anti-CCR4 monoclonal antibody].
Yamamoto K. Yamamoto K. Nihon Rinsho. 2015 Feb;73 Suppl 2:224-8. Nihon Rinsho. 2015. PMID: 25831757 Japanese. No abstract available.
Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model.
Chang DK, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, Matulonis U, Zhu Q, Marasco WA. Chang DK, et al. Oncoimmunology. 2015 Dec 10;5(3):e1090075. doi: 10.1080/2162402X.2015.1090075. eCollection 2016 Mar. Oncoimmunology. 2015. PMID: 27141347 Free PMC article.
Recent studies have demonstrated that regulatory T cells (Tregs) are recruited to tumor sites where they can suppress antitumor immunity. The chemokine receptor CCR4 is expressed at high levels on functional CD4(+)CD25(+)FoxP3(+) Tregs and production of the CCR4 lig …
Recent studies have demonstrated that regulatory T cells (Tregs) are recruited to tumor sites where they can suppress antitumor immunity. Th …
Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.
Musiek ACM, Rieger KE, Bagot M, Choi JN, Fisher DC, Guitart J, Haun PL, Horwitz SM, Huen AO, Kwong BY, Lacouture ME, Noor SJ, Rook AH, Seminario-Vidal L, Vermeer MH, Kim YH. Musiek ACM, et al. Dermatol Ther (Heidelb). 2022 Jan;12(1):29-40. doi: 10.1007/s13555-021-00624-7. Epub 2021 Nov 23. Dermatol Ther (Heidelb). 2022. PMID: 34816383 Free PMC article. Review.
The CCR4-directed monoclonal antibody mogamulizumab has been shown to significantly improve progression-free survival and overall response rate compared with vorinostat in adults with relapsed/refractory mycosis fungoides (MF) and Sezary syndrome (SS). ...
The CCR4-directed monoclonal antibody mogamulizumab has been shown to significantly improve progression-free survival a …
328 results